Innovative Therapy that "Tricks" and Destroys Cancer Cells Advances to Clinical Trial

Rhea-AI Summary

A novel therapy for glioblastoma, developed at the Medical College of Wisconsin, has progressed to clinical trials. This oral treatment, gallium maltolate (GaM), shows promising results in preclinical studies by significantly slowing tumor growth. Led by Dr. Christopher Chitambar, the trial aims to evaluate GaM's effectiveness against this aggressive brain cancer, with an expected completion date of December 2025. The trial is sponsored by Imaging Biometrics, a subsidiary of IQ-AI Ltd., supported by grants from the Musella Brain Tumor Foundation and MCW Cancer Center.

Positive

• Gallium maltolate (GaM) shows significant promise in slowing glioblastoma growth in preclinical studies.
• The clinical trial aims to provide a novel oral treatment option for glioblastoma patients.
• The trial is supported by credible institutions and collaborative scientists, enhancing its credibility.

Negative

• The treatment's effectiveness and safety are yet to be proven in clinical settings.

Results from pre-clinical research show iron-like compound holds promise for treating patients with glioblastoma, an aggressive brain cancer

MILWAUKEE , April 8, 2022 /PRNewswire/ -- A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.

Despite decades of research globally, only incremental gains have been made to extend or enhance quality of life for patients with glioblastoma. Treatment options are limited and typically include a combination of surgery, radiation therapy, and chemotherapy. Now, a new clinical study open at Froedtert & the Medical College of Wisconsin will evaluate an alternative treatment that is administered orally.

The treatment evolved from years of research led by Christopher Chitambar, MD, and his lab to study iron-dependent processes in cancer biology and the mechanisms by which gallium compounds target iron metabolism and block malignant cell growth. In preclinical studies, Drs. Chitambar and Kathleen Schmainda, PhD, discovered that gallium maltolate (GaM) significantly slowed the growth, and reduced the size, of glioblastoma.

GaM, originally developed by Harvard and Stanford educated scientist Lawrence R. Bernstein, PhD, is an orally available form of the metal gallium, which, in the body, shares many chemical properties with the highly oxidized form of iron, called Fe(III). Numerous studies examining the relationship between iron and cancer show that increased levels of iron in the body can be associated with increased cancer risk and severity, because cancer cells depend on iron to multiply and spread. Because of gallium's similarity to Fe(III), it enters cancer cells instead of iron, preventing their multiplication.

"The discovery that GaM has anticancer activity against glioblastoma in pre-clinical studies is extremely exciting; it opens the door for developing it as a drug for treatment of glioblastoma in patients," says Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW. "The anticancer mechanism of GaM applies to other solid tumors as well," he adds.

Jennifer Connelly, MD, Associate Professor of Neurology at MCW, is Principal Investigator (PI) of the clinical trial with Dr. Chitambar serving as co-PI and Chair. Both are long-standing collaborators with Kathleen Schmainda, PhD, a co-founder of Imaging Biometrics, LLC, and a recognized leader in brain tumor imaging. Dr. Bernstein is participating as a co-investigator.

The trial is being sponsored by Imaging Biometrics with supporting grants from the Musella Brain Tumor Foundation and the MCW Cancer Center. Based in Elm Grove, WI, Imaging Biometrics is a wholly owned subsidiary of IQ-AI Ltd.

With over a decade of experience in quantitative brain tumor imaging analysis, including analysis for several national multi-center trials, Imaging Biometrics will provide image analysis solutions for evaluating the response to GaM. "We are working with an excellent team of scientists and clinicians, and everyone is eager to move this study forward," says Michael Schmainda , CEO of Imaging Biometrics. 

The trial, being conducted at Froedtert & the Medical College of Wisconsin, is currently accepting participants and has an anticipated completion date of December 2025.

About the Medical College of Wisconsin

With a history dating back to 1893, the Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research and community engagement. More than 1,500 students are enrolled in MCW's medical school and graduate school programs in Milwaukee, Green Bay and Central Wisconsin. MCW's School of Pharmacy opened in 2017. A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin. In the last ten years, faculty received more than $1.6 billion in external support for research, teaching, training and related purposes. This total includes highly competitive research and training awards from the National Institutes of Health (NIH). Annually, MCW faculty direct or collaborate on more than 3,100 research studies, including clinical trials. Additionally, more than 1,650 physicians provide care in virtually every specialty of medicine for more than 4 million patients annually.

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (OTCQB: IQAIF, LON:IQAI), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform- independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

View original content:https://www.prnewswire.com/news-releases/innovative-therapy-that-tricks-and-destroys-cancer-cells-advances-to-clinical-trial-301520494.html

SOURCE Medical College of Wisconsin

FAQ

What is the purpose of the glioblastoma clinical trial involving gallium maltolate (IQAIF)?

The trial aims to evaluate the effectiveness and safety of gallium maltolate (GaM) as a treatment for glioblastoma.

What are the preclinical results of gallium maltolate (IQAIF) for glioblastoma?

Preclinical studies indicate that gallium maltolate significantly slows tumor growth in glioblastoma.

When is the glioblastoma clinical trial with gallium maltolate (IQAIF) expected to complete?

The clinical trial is anticipated to be completed by December 2025.

Who is sponsoring the clinical trial for gallium maltolate (IQAIF)?

The trial is sponsored by Imaging Biometrics with support from the Musella Brain Tumor Foundation and the MCW Cancer Center.

What is the significance of gallium maltolate (IQAIF) in cancer treatment?

Gallium maltolate's mechanism may allow it to enter cancer cells in place of iron, potentially blocking their growth.